Designation of Phenethyl Halides as List I Chemicals
DEA proposes to designate phenethyl halides as List I chemicals, imposing new registration, recordkeeping, and reporting requirements on manufacturers, distributors, importers, and exporters. This targets chemicals used in illicit fentanyl production.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. API and contract manufacturers, generic/ANDA manufacturers, and any entity handling phenethyl halides should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comment period ends 60 days after publication (approx. Sep 7, 2026); effective date likely 30-90 days after final rule.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Phenethyl halides would become List I chemicals under the CSA, requiring DEA registration, import/export declarations, and enhanced security and recordkeeping.
Who it affects
API and contract manufacturers, generic/ANDA manufacturers, and any entity handling phenethyl halides
What you must do
Review current handling of phenethyl halides; prepare to register with DEA and implement compliance measures.
Deadline
Comment period ends 60 days after publication (approx. Sep 7, 2026); effective date likely 30-90 days after final rule.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness